TiGenix is aiming to net $42.9 million in a Nasdaq IPO, approximately half of which will go toward a U.S. late-phase trial of Crohn's disease candidate…

After a torrid year that has seen multiple deaths in testing, FDA- and self-imposed study halts and its shares tanking, Juno last night held up to the light…

John Jenkins is retiring from the FDA's office for new drugs next year, with Janet Woodcock set to run the office in the interim.

British biotech ReNeuron has posted generally encouraging midstage data which showed their stem cell therapy could help certain stroke patients move their arms…

Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early…

UniQure has posted fresh data linking its hemophilia B gene therapy to the near-cessation of spontaneous bleeding.

Boehringer is slashing its head count by 244, with the bulk of the cutbacks affecting its small-molecule discovery operations in Ridgefield.

Japanese Big Pharma Takeda and VC Lightstone have come together to launch Cerevance, a newco focused on neuroscience R&D for neurological and psychiatric…

R&D